SCI & TECH● LOWSep 3 · Sep 3, 2026, 5:55 AM
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Seeking Alpha Tech · global
Ultragenyx shares dropped following the failure of a Phase 3 trial for its Angelman syndrome drug. This outcome is a significant setback for the company's pharmaceutical development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH40m agoPsychology says some people prefer to spend time alone, dedicate several hours to their personal interests, and avoid conversations they consider unstimulating. Although they can maintain satisfactory relationships, they do not always feel the need to participate in meetings or activitiesClarínSCI & TECH51m agoWATCH: David Muir reports on the beloved barn owls that have made Manhattan homeABC NewsSCI & TECH56m agoHow smart will Hong Kong’s ‘AI city brain’ be?South China Morning PostSCI & TECH1h agoChina’s villages pay the price for Beijing’s AI ambitionsFinancial Times